嵌合抗原受体自然杀伤细胞疗法：克服肿瘤学挑战的变革性方法。
CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges.
机构信息
China Key Laboratory for Early Diagnosis and Biotherapy of Malignant Tumors in Children and Women, Dalian Women and Children's Medical Group, Dalian 116012, China.
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
出版信息
Biomolecules. 2024 Aug 20;14(8):1035. doi: 10.3390/biom14081035.
The use of chimeric antigen receptor (CAR) in natural killer (NK) cells for cancer therapy is gaining momentum, marking a significant shift in cancer treatment. This review aims to explore the potential of CAR-NK cell therapy in cancer immunotherapy, providing a fresh perspective. It discusses the innovative approaches in CAR-NK cell design and engineering, particularly targeting refractory or recurrent cancers. By comparing CAR-NK cells with traditional therapies, the review highlights their unique ability to tackle tumor heterogeneity and immune system suppression. Additionally, it explains how novel cytokines and receptors can enhance CAR-NK cell efficacy, specificity, and functionality. This review underscores the advantages of CAR-NK cells, including reduced toxicity, lower cost, and broader accessibility compared to CAR-T cells, along with their potential in treating both blood cancers and solid tumors.
嵌合抗原受体 (CAR) 在自然杀伤 (NK) 细胞中的应用在癌症治疗中逐渐兴起，标志着癌症治疗的重大转变。本综述旨在探讨 CAR-NK 细胞疗法在癌症免疫治疗中的潜力，提供新的视角。它讨论了 CAR-NK 细胞设计和工程方面的创新方法，特别是针对难治性或复发性癌症。通过将 CAR-NK 细胞与传统疗法进行比较，该综述强调了它们独特的解决肿瘤异质性和免疫系统抑制的能力。此外，它解释了新型细胞因子和受体如何增强 CAR-NK 细胞的疗效、特异性和功能。本综述强调了 CAR-NK 细胞的优势，包括与 CAR-T 细胞相比，毒性降低、成本降低和更广泛的适用性，以及它们在治疗血液癌和实体瘤方面的潜力。
Zotero 插件